hrp0094p2-233 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

Diazoxide Responsive Congenital Hyperinsulinism

Lohiya Nikhil , Cassidy Kelly , Yung Zoe , Erlandson-Parry Karen , Wright Samantha , Gait Lucy , Didi Mohammed , Senniappan Senthil ,

Introduction: Congenital Hyperinsulism (CHI) is a common cause of recurrent and persistent hypoglycemia in the neonatal period. Diazoxide is the first line medication used for the management of CHI. We report the clinical profile and the management outcome of a large cohort of patients with diazoxide responsive CHI.Methodology: A retrospective data collection including antenatal, perinatal and postnatal clinical parameters, laboratory di...

hrp0095p1-354 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Single centre experience of using 6 monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohammed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Mounting evidence points to an association between increased glucocorticoid (GC) action and weight gain. However, the response to GCs is not only determined by GC serum concentrations, but also by individual differences in tissue-specific sensitivity, influenced by genetic and acquired (e.g. disease-related) factors. The extent to which differences in GC sensitivity may influence development of (abdominal) obesity, or vice versa, is poorly understo...